Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website. 

The first such large scale centre to be set up by Oxford Health NHS Foundation Trust, the Kassam Stadium, home to the city’s League One football side, will be open to the public by invite-only, seven days a week, from 8am to 8pm, as part of the national effort to vaccinate against COVID-19.  

Prof. Pollard said:  

‘To see a vaccination centre in Oxford delivering the vaccine that was developed in the city is a great moment. So much hard work has gone into getting to this stage from the researchers developing the vaccine and the Oxford Health team making all the arrangements to set up and run an efficient vaccination centre. Many volunteers from Oxfordshire took part in the clinical trials and it is a huge credit to their commitment that we can benefit from this vaccine today. 

‘We anticipate that the vaccination of as many people as possible as soon as possible will start to have a big impact on hospitalisations and is something everyone has been hoping for. However, vaccination is only one part of the story - people should continue to follow public health measures, such as observing the rules of lockdown, social distancing, wearing masks and washing their hands until we get the virus back under control.’  

The new vaccination centre will kick off by vaccinating priority front line patient-facing staff who work on community and mental health wards as well as in the community via services like district nursing, before opening its doors to patients.  

People aged 75 and over will shortly be invited via the national booking system to make an appointment for their first vaccination of the Oxford AstraZeneca vaccine at the Kassam. If they cannot or do not want to travel to a vaccination centre people can wait to be invited to be immunised by a local GP service or hospital hub.  

People are reminded not to turn up to the Kassam Stadium without an appointment. 

Similar stories

One billion doses: A moment to celebrate but not a time to be complacent

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.

Severe disease, not mild infection, makes a pandemic – vaccines still offer our best hope

If the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.